Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review

Author:

André Louise,Antherieu Gabriel,Boinet Amélie,Bret Judith,Gilbert ThomasORCID,Boulahssass RabiaORCID,Falandry ClaireORCID

Abstract

Fatigue is a highly prevalent symptom in both cancer patients and the older population, and it contributes to quality-of-life impairment. Cancer treatment-related fatigue should thus be included in the risk/benefit assessment when introducing any treatment, but tools are lacking to a priori estimate such risk. This scoping review was designed to report the current evidence regarding the frequency of fatigue for the different treatment regimens proposed for the main cancer indications, with a specific focus on age-specific data, for the following tumors: breast, ovary, prostate, urothelium, colon, lung and lymphoma. Fatigue was most frequently reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) versions 3 to 5. A total of 324 regimens were analyzed; data on fatigue were available for 217 (67%) of them, and data specific to older patients were available for 35 (11%) of them; recent pivotal trials have generally reported more fatigue grades than older studies, illustrating increasing concern over time. This scoping review presents an easy-to-understand summary that is expected to provide helpful information for shared decisions with patients regarding the anticipation and prevention of fatigue during each cancer treatment.

Funder

Teva Pharmaceuticals

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference315 articles.

1. PDQ Supportive and Palliative Care Editorial Board Fatigue (PDQ®): Health Professional Version,2002

2. Fatigue: Relevance and implications in the aging population

3. Evidence Report on the Occurrence, Assessment, and Treatment of Fatigue in Cancer Patients

4. Patient, Caregiver, and Oncologist Perceptions of Cancer-Related Fatigue: Results of a Tripart Assessment Survey. The Fatigue Coalition;Vogelzang;Semin. Hematol.,1997

5. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3